Brave Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $277K | Sell |
4,800
-340
| -7% | -$19.5K | 0.06% | 119 |
|
|
2026
Q1 | $312K | Buy |
5,140
+740
| +17% | +$43.1K | 0.07% | 119 |
|
|
2025
Q4 | $237K | Buy |
+4,400
| New | +$212K | 0.06% | 134 |
|
|
2025
Q3 | – | Sell |
-4,400
| Closed | -$204K | – | 173 |
|
|
2025
Q2 | $204K | Sell |
4,400
-1,250
| -22% | -$61.4K | 0.05% | 140 |
|
|
2025
Q1 | $345K | Sell |
5,650
-750
| -12% | -$43.7K | 0.11% | 92 |
|
|
2024
Q4 | $362K | Hold |
6,400
| – | – | 0.11% | 86 |
|
|
2024
Q3 | $331K | Buy |
+6,400
| New | +$300K | 0.08% | 99 |
|
|
2023
Q3 | – | Sell |
-3,639
| Closed | -$233K | – | 155 |
|
|
2023
Q2 | $233K | Buy |
3,639
+70
| +2% | +$4.69K | 0.07% | 113 |
|
|
2023
Q1 | $247K | Sell |
3,569
-90
| -2% | -$6.35K | 0.08% | 106 |
|
|
2022
Q4 | $263K | Hold |
3,659
| – | – | 0.09% | 103 |
|
|
2022
Q3 | $260K | Hold |
3,659
| – | – | 0.13% | 92 |
|
|
2022
Q2 | $282K | Hold |
3,659
| – | – | 0.13% | 93 |
|
|
2022
Q1 | $267K | Hold |
3,659
| – | – | 0.09% | 112 |
|
|
2021
Q4 | $228K | Hold |
3,659
| – | – | 0.06% | 125 |
|
|
2021
Q3 | $217K | Sell |
3,659
-100
| -3% | -$6.59K | 0.06% | 126 |
|
|
2021
Q2 | $251K | Hold |
3,759
| – | – | 0.07% | 119 |
|
|
2021
Q1 | $237K | Sell |
3,759
-300
| -7% | -$18.7K | 0.08% | 119 |
|
|
2020
Q4 | $252K | Buy |
+4,059
| New | +$250K | 0.1% | 105 |
|
|
2016
Q4 | – | Sell |
-1,200
| Closed | -$65K | – | 177 |
|
|
2016
Q3 | $65K | Hold |
1,200
| – | – | 0.04% | 204 |
|
|
2016
Q2 | $88K | Hold |
1,200
| – | – | 0.06% | 180 |
|
|
2016
Q1 | $77K | Hold |
1,200
| – | – | 0.05% | 191 |
|
|
2015
Q4 | $83K | Hold |
1,200
| – | – | 0.06% | 184 |
|
|
2015
Q3 | $71K | Hold |
1,200
| – | – | 0.05% | 186 |
|
|
2015
Q2 | $80K | Hold |
1,200
| – | – | 0.06% | 185 |
|
|
2015
Q1 | $77K | Hold |
1,200
| – | – | 0.05% | 185 |
|
|
2014
Q4 | $71K | Hold |
1,200
| – | – | 0.05% | 186 |
|
|
2014
Q3 | $61K | Hold |
1,200
| – | – | 0.05% | 202 |
|
|
2014
Q2 | $58K | Hold |
1,200
| – | – | 0.04% | 209 |
|
|
2014
Q1 | $62K | Hold |
1,200
| – | – | 0.05% | 193 |
|
|
2013
Q4 | $64K | Buy |
+1,200
| New | +$61.1K | 0.05% | 194 |
|
Other funds holding BMY
Brave Asset Management's BMY Position: Q2 2026 in Review
Brave Asset Management reduced its Bristol-Myers Squibb (BMY) stake by 6.6% in Q2 2026, selling an estimated $19.5K and leaving 4,800 shares worth $277K. The position accounts for 0.06% of the portfolio, ranked #119.
Brave Asset Management first reported a position in BMY in Q4 2013 and has held it in 30 quarters since. The position peaked at $362K in Q4 2024. 2,523 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Brave Asset Management held 4,800 shares of Bristol-Myers Squibb worth $277K as of Q2 2026.
- Brave Asset Management sold 340 Bristol-Myers Squibb shares in Q2 2026, an estimated $19.5K.
- Bristol-Myers Squibb made up 0.06% of Brave Asset Management's portfolio in Q2 2026, its #119 holding.
- Brave Asset Management first reported a position in Bristol-Myers Squibb in Q4 2013 and has held it in 30 quarters since.
- Brave Asset Management's Bristol-Myers Squibb position peaked at $362K in Q4 2024.
- 2,523 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Brave Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.